Friedrich S, Cheng Y L, Saville B
Department of Chemical Engineering and Applied Chemistry, University of Toronto, Canada.
Curr Eye Res. 1997 Jul;16(7):663-9. doi: 10.1076/ceyr.16.7.663.5061.
The purpose of this study was to determine how the position and volume of an intravitreal injection affect the distribution and elimination of drug from the vitreous humor.
A mathematical model that had been developed and used previously to study drug distribution in the vitreous humor of the rabbit eye was modified to match the physiology of the human eye. Fluorescein and fluorescein glucuronide were used as the model compounds for these studies. Four extreme injection locations were considered: a central injection, an injection displaced towards the retina, an injection displaced towards the lens, and an injection displaced toward the hyaloid membrane. Injections containing an equal mass of drug dissolved in volumes of either 15 microL or 100 microL were compared.
The location of an intravitreal injection was found to have a substantial effect on elimination and distribution in the vitreous. Peak concentrations at different vitreous locations varied by over three orders of magnitude, depending on the injection location. The mean concentration of drug remaining in the vitreous 24 hours after the intravitreal injection varied by up to a factor of 3.8, depending on the injection location. Changing the volume of the injection from 15 microL to 100 microL dampened the effects of the initial injection location; however, meant concentrations at 24 hours still varied by up to a factor of 2.5.
Careful control of the conditions of an intravitreal injection could reduce treatment variability, improve bioavailability, and reduce the possibility of retinal toxicity.
本研究旨在确定玻璃体内注射的位置和体积如何影响药物在玻璃体液中的分布和消除。
对先前开发并用于研究兔眼玻璃体液中药物分布的数学模型进行修改,以匹配人眼的生理情况。荧光素和荧光素葡糖醛酸用作这些研究的模型化合物。考虑了四个极端注射位置:中央注射、向视网膜方向移位的注射、向晶状体方向移位的注射以及向玻璃体膜方向移位的注射。比较了含有等量药物且溶解于15微升或100微升体积中的注射情况。
发现玻璃体内注射的位置对玻璃体中的消除和分布有重大影响。不同玻璃体位置的峰值浓度根据注射位置的不同变化超过三个数量级。玻璃体内注射24小时后玻璃体中剩余药物的平均浓度根据注射位置的不同变化高达3.8倍。将注射体积从15微升改为100微升可减弱初始注射位置的影响;然而,24小时时的平均浓度仍变化高达2.5倍。
仔细控制玻璃体内注射的条件可减少治疗变异性、提高生物利用度并降低视网膜毒性的可能性。